With the advent of novel treatments including IDH inhibitors [14, 15], the value of DSC MR perfusion may extend further than pre-treatment genotyping of gliomas, allowing treatment selection and surveillance through the identification of genotype-driven vascular signatures. Here, IDH1 is linked to central nervous system cancer.